ABK Biomedical Inc.

ABK Biomedical is a clinical-stage medical device company specializing in radioembolization and embolization technologies for cancer treatment, particularly hepatocellular carcinoma and hypervascular tumors. The company develops and commercializes proprietary imageable microsphere products designed for interventional radiology procedures. Key product lines include Eye90 microspheres, a novel yttrium-90 radioembolization technology with proprietary glass composition enabling in-procedure visualization for unresectable liver cancer, and Easi-Vue embolic microspheres, an imageable bland embolization product cleared by FDA 510(k) for treating arteriovenous malformations and hypervascular tumors. ABK Biomedical is currently conducting the Route90 pivotal clinical study evaluating Eye90 in unresectable hepatocellular cancer; enrollment was recently completed. The company holds ISO 13485 certification for medical device quality management and maintains partnerships with leading academic institutions and research organizations including Dalhousie University, NC State University, MD Anderson Cancer Center, Northwestern University, and the University of Missouri Research Reactor (MURR). Manufacturing partnerships include agreements with COR Development and Paragon Medical. The company operates as a research and development organization with headquarters in Halifax, Nova Scotia, Canada, and a development office in Orange County, California. Eye90 microspheres remain investigational and are not FDA-approved for commercial use.